Start here if you're new
what it is
Mineralys is a biotech trying to sell lorundrostat, a pill for hard-to-control high blood pressure.
how it gets paid
Last year Mineralys Therap made n/a in revenue. Lorundrostat development was the main engine at $0M, or 25% of sales.
what just happened
Mineralys posted a -$1.94 quarter with no revenue on the board.
At a glance
B+ balance sheet — decent shape, but not bulletproof
-$3.66 fy2024 eps est
1.5 beta
~$2B market cap
mid cap
xvary composite: 65/100 — average
What they do
Mineralys is a biotech trying to sell lorundrostat, a pill for hard-to-control high blood pressure.
Lorundrostat targets patients who still miss 130/80 mmHg after 2 or 3 drugs. That is the biotech version of trying to sell a parachute after the first two failed. You are betting on one oral pill, one FDA path, and 51 employees.
How they make money
n/a
annual revenue
Lorundrostat development
$0M
Uncontrolled hypertension
$0M
Resistant hypertension
$0M
Business planning and capital raising
$0M
The products that matter
balance sheet reality
cash runway
n/a
In clinical biotech, runway is not bookkeeping. It is permission to keep the thesis alive long enough to test it.
foundation
lead program
lorundrostat
main catalyst
Lorundrostat is doing the heavy narrative lifting. If the data work, the equity story changes fast. If they do not, it changes faster.
catalyst
what would reduce the binary setup
pipeline depth
thin from this page
Every biotech wants to be more than one asset. This page does not give you enough proof yet. Until it does, diversification is more aspiration than fact.
future
Key numbers
-$3.66
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 1 — safer than 95% of stocks
- price stability 5 / 100
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for MLYS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Mineralys posted a -$1.94 quarter with no revenue on the board.
The latest quarter still showed no reported revenue. Losses were 273% worse than a year earlier.
$0M
revenue
$1.94
eps
n/a
n/a
loss per share
The quarter lost $1.94 a share, and that was before revenue showed up.
SEC filing, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
this story breaks on three things, and all three point back to the same problem: one main asset, no revenue cushion, and a market already paying up for progress.
med
lorundrostat disappoints
If the key dataset misses, the whole equity story gets repriced in one move. That is what single-asset biotech looks like.
impact: could take 40–70% off the stock
med
cash burn forces dilution
No revenue means time has to be purchased with cash. If timelines slip, new capital usually shows up at a worse price than you wanted.
impact: existing holders get diluted before the next major readout
med
the single-program setup never broadens
Even if the science stays alive, the stock can stall if the company does not prove it is more than lorundrostat. One asset can carry a story. It rarely carries a full franchise premium.
impact: upside stays capped even without a catastrophic miss
Here is the kill criterion in plain English: if Mineralys cannot show either better funding visibility or a second meaningful clinical path, the one-asset discount stays earned.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next company update
Use the next update to judge whether management is merely buying time or actually reducing uncertainty. Last full review: updated feb 20, 2026.
metric
funding visibility
This is the number that matters before revenue exists. If disclosures make the runway clearer, the stock gets breathing room. If they do not, dilution moves closer to center stage.
risk
lorundrostat data risk
The page already tells you where the story can break. Watch the science first and the chart second.
trend
volatility around catalysts
With a 1.5 beta and 5 / 100 price stability, this stock tends to move harder than the market when headlines hit. Welcome to clinical biotech.
Analyst rankings
short-term outlook
mixed
target data is thin here. in human-speak, nobody has a clean consensus worth pretending is precise.
risk profile
volatile
a 1.5 beta and 5 / 100 price stability tell you this will not trade like a sleepy large cap.
chart momentum
catalyst-driven
this name trades more on trial and financing signals than on smooth trend lines.
earnings predictability
40 / 100
predictability stays low because the underlying business is still pre-commercial and funding-dependent.
source: institutional data
Institutional activity
institutional ownership data for MLYS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$32
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive